Articles tagged with Osteoblasts
Researchers identify bone-forming cells as driver of scoliosis caused by NF1. Blocking RAS-MAPK signaling pathway with medications halts progression of spinal deformity in genetically engineered mouse model.
Researchers found signs of osteomyelitis in sauropod fossils from the Cretaceous period, suggesting a fatal bone disease that killed animals quickly. The study identified three previously unknown manifestations of osteomyelitis and provides insights into the environment that favored pathogens.
Scientists at Leipzig University have discovered that the adhesion G protein-coupled receptor GPR133 plays a central role in building and maintaining healthy bone. By mimicking natural activation, a new active substance AP503 can strengthen bones and potentially treat osteoporosis.
Researchers found that disabling mERα signaling in osteoblast lineage cells reduced cortical bone mass and density, leading to weaker bones. This pathway is essential for maintaining bone strength and density, especially in females.
Researchers investigated why bones become less responsive to exercise with age, finding increased mtROS or decreased Atg7-dependent autophagy in osteoblastic cells do not contribute to reduced mechanoresponsiveness. Damage to the bone's osteocyte network also does not prevent a healthy bone-building response.
Researchers identify Fam102a as a key regulator of both osteoclast and osteoblast differentiation, leading to enhanced osteoblast formation and bone volume. The study reveals significant protein-protein interactions involving Fam102a and Kpna2, shedding light on the critical molecular interactions involved in bone remodeling.
A team of researchers discovered a protein that blocks bone-forming cells by preventing them from maturing. The study found that the protein CLEC14A reduces bone formation, while its absence leads to increased mineralized bone tissue.
Researchers are studying the role of stress hormones and mineralocorticoid receptors in bone health as we age. The goal is to understand how balance between these factors affects our skeletons. By investigating this complex relationship, scientists hope to develop new insights into osteoporosis and other age-related bone disorders.
A research team from Osaka University identified a key osteoporosis-related gene, Men1, and developed a new animal model of the disease. The study found that inactivation of Men1 led to cellular senescence in osteoblasts, reducing bone formation activity and increasing bone resorption.
Researchers have identified a novel target downstream of parathyroid hormone signaling that suppresses bone formation. Gprc5a negatively regulates osteoblast proliferation and differentiation by partially suppressing BMP signaling, potentially increasing teriparatide effectiveness in non-responding patients.
Researchers at the University of Birmingham have identified PEPITEM, a naturally occurring peptide, as a promising new therapy for osteoporosis and other bone disorders. The study found that PEPITEM enhances bone mineralisation, formation, and strength, and reverses bone loss in animal models.
Researchers developed a new treatment method using plasma irradiation to speed up bone healing. The study found that displaced fractures exhibited stronger unions than nonirradiated ones, with strength increased by 3.5 times.
Researchers found that chlorogenic acid enhances osteoblast proliferation and differentiation, while inhibiting RANKL-induced osteoclastogenesis. Administration of chlorogenic acid antagonizes ovariectomized-induced bone loss in rats.
Researchers at São Paulo State University developed a novel biomaterial that speeds up osteoblast differentiation, mimicking a low-oxygen environment. The cobalt-doped calcium phosphate material has the potential to be used in future bone regeneration procedures, reducing surgery risks and hospital stays.
A team from Tokyo Medical and Dental University has developed a technique to improve bone regeneration over large areas in rats, using vascular endothelial growth factor (VEGF) and Runx2. The combination of these two RNAs led to better regenerative responses in bone cells than each RNA alone.
Long-term use of systemic antibiotics can alter the gut microbiome, leading to reduced bone mass accrual and impaired skeletal maturation. Researchers found that minocycline therapy causes changes to the gut microbiome, disrupting normal communication between the liver and small intestine.
A new calculator will assess an individual's risk and benefit of taking bisphosphonates for osteoporosis, considering factors such as fracture history and comorbid conditions. The calculator aims to provide personalized guidance on whether a drug holiday is beneficial or not.
Researchers at MUSC found that extracting and isolating Treg cells and transplanting them back into the same system successfully treats osteogenesis imperfecta for a year. The treatment results in stronger bones, increased osteoblast numbers, and decreased osteoclast numbers.
A study found that elevated blood levels of chemokine CXCL9 predict the risk of osteoporotic hip fracture in men. Researchers discovered a significant association between CXCL9 and hip fractures in a cohort of Chinese men, highlighting the potential for early interventions targeting CXCL9 to prevent hip fractures.
A study identified an 18-base osteogenetic ODN (iSN40) that promotes the differentiation of mouse osteoblasts and induces the expression of genes required for bone formation. This discovery offers a promising treatment option for osteoporosis, which affects 200 million people worldwide.
Researchers at Osaka University used advanced microscopy to visualize extracellular vesicles secreted by osteoblasts, identifying a subset that limits bone formation and stimulates osteoclast differentiation. This finding could lead to new treatments for bone diseases.
Researchers at Columbia University Irving Medical Center have found that targeting neighboring bone cells may be a better strategy than directly targeting blood cancer stem cells. By blocking the communication between leukemia cells and osteoblasts, the study suggests a new approach to treat acute myeloid leukemia.
Researchers have found that blocking mineralocorticoid receptors, a key factor in bone health, may help protect against bone loss and osteoporosis. This new target is thought to be more effective than previously believed logical targets, such as reducing glucocorticoid receptor activity.
A new study by researchers at Mount Sinai found that a specific gene, HHIP, helps regulate the development of the coronal suture, a fibrous joint that connects the front and middle bone plates. The study showed that embryos with a missing HHIP gene had misshapen skulls and fewer mesenchymal cells separating the bones.
Scientists have discovered a way to replace mutated osteoblasts with healthy ones, leading to improved collagen production and potentially paving the way for a cure for brittle bone disease. The breakthrough could be translated to other forms of OI and bone diseases in the future.
A substance from Saussurea controversa has been found to promote bone regeneration by stimulating the conversion of stem cells into osteoblasts. The calcium chelidonate was tested in vitro and in vivo, showing non-toxic effects and increased viable stem cells at low doses.
Researchers discovered that physical load stimulates bone growth through the expression of osteocrin (OSTN), a peptide produced by osteoblasts. OSTN is critical to regulating bone growth and physical endurance, with its expression decreasing when load is reduced and increasing with load stimulation.
Researchers at Osaka University identified SLPI as a critical mediator in balancing bone build-up and break-down, mediated by parathyroid hormone. The molecule promotes bone formation and suppresses bone loss, suggesting potential new treatments for osteoporosis.
Researchers induced KLF2 in dental pulp-derived stem cells to promote osteoblast differentiation and increase bone growth. The study aims to reduce the occurrence and severity of rheumatoid arthritis, osteoporosis, and other bone diseases.
A recent study has discovered a cell type that governs bone formation and maintenance, shedding light on the mechanisms behind osteoporosis. Researchers found that bone marrow adipogenic lineage precursors (MALPs) play a distinct role in regulating bone remodeling, and targeting these cells could lead to more effective therapies.
A recent study published in Communications Biology reveals that osteoblasts use extracellular vesicles to send signaling molecules to immature osteoclasts, triggering their differentiation into mature cells. This process is crucial for bone repair and regeneration after a fracture.
A study published in JCI Insight found that Apolipoprotein E interferes with bone healing in older individuals, leading to weaker bones and increased risk of re-fracture. Researchers discovered that reducing ApoE levels can reverse aging effects on the bones, promoting faster and more effective healing.
A recent study published in Nature Communications has identified SIRT7 as a key enzyme in regulating bone formation. The researchers found that SIRT7 deacylates the 368th lysine residue of SP7/Osterix, leading to increased osteoblast differentiation and bone density.
Researchers used intravital two-photon microscopy to visualize interactions between osteoblasts and osteoclasts in living bone tissue. They found that osteoblasts can inhibit bone resorption by direct contact with osteoclasts, demonstrating an important concept for regulating bone homeostasis.
A new study reveals that a population of progenitor cells, marked by high expression of matrix metalloproteinase 9, provides osteoblasts during bone regeneration. These cells are derived from embryonic somites and reserved in niches of bone-forming tissues in adult animals.
Aging is associated with a decrease in Cbf-beta protein, leading to an imbalance in bone maintenance and increased fat cell creation. Maintaining Cbf-beta may be essential to preventing age-associated osteoporosis.
Teriparatide therapy increases osteoblast activity and lifespan, but stopping treatment leads to increased fat cell formation in mice. This suggests therapies targeting parathyroid hormone receptors may prioritize osteoblast development over other cell fates.
A novel microdevice provides a minimally invasive method for measuring cell mechanical properties, improving upon existing techniques such as atomic-force microscopy. The device uses a soft diaphragm to compress cells, allowing real-time observation of deformation and estimation of the Young's modulus.
Researchers found immediate changes in gene expression of osteoblasts and osteoclasts in medaka fish exposed to microgravity. The study suggests a new area of research in gravitational biology, exploring the molecular mechanisms behind bone structure changes.
Researchers have discovered how zebrafish rebuild their skeleton after losing parts of their fins. A critical enzyme called Cyp26b1 helps to regulate retinoic acid levels, allowing osteoblasts to revert and form new bone tissue. The regeneration process relies on a complex navigation system involving signaling proteins and cell types.
A team of researchers has developed a 'self-fitting' material that can precisely fill bone defects in the head, face, and jaw, providing a potential solution for reconstructing facial features after injuries or surgery. The material, made from a shape-memory polymer, expands with warm salt water to conform to irregular defect shapes.
Researchers found that Frizzled-9 upregulates during osteoblast differentiation and is essential for bone mineralization. Mice lacking Fzd9 have fragile bones due to low rates of bone formation, highlighting its potential as a drug target for treating osteoporosis.
Two new studies reveal a key molecular link between bone remodeling and metabolism, finding that osteocalcin levels are tied to insulin resistance and glucose intolerance. Osteocalcin treatment improves symptoms in mice with diabetes-like conditions.
Researchers discovered a key compound, PGE2, that quickly restores blood cell production and continues to do so for six to eight weeks after bone marrow injury. This treatment could represent a precise way to accelerate recovery from life-threatening blood cell shortages.
The protein Atf4 plays a crucial role in regulating energy generation in osteoblasts, which control biochemical reactions that produce energy. Mice lacking Atf4 exhibit lower fat mass and blood glucose levels due to increased insulin sensitivity, highlighting the importance of Atf4 in glucose metabolism.
Researchers have identified a new gene, PTRF, which causes mutations leading to muscle weakness and lipodystrophy. The study found that these individuals had deficient caveolin-3 protein in their muscles, despite no mutations in the caveolin-3 gene.
A breakthrough study has revealed that blood stem cells produce chemical signals of their own that influence their attachment to the bone marrow or migration into the circulatory system. This discovery holds implications for improving leukemia treatment and artificially culturing infection-fighting immune cells.
A multi-centre study found that osteoblast cell injections accelerated fracture healing, with increased bone growth and no significant patient complications. The treatment is considered a safe and effective alternative to traditional methods, allowing for faster recovery without surgery.
Dr. Franceschi is being recognized for his scientific contributions to mineralized tissue research, including the discovery of vitamin D regulation targets and the development of gene therapy approaches for bone regeneration. He will receive the award at the IADR 86th General Session & Exhibition in Toronto on July 2, 2008.
Researchers at the University at Buffalo have discovered that estradiol helps maintain bone density by stopping the activation of caspase-3, an enzyme involved in osteoblast apoptosis. This finding suggests that estrogens may prevent both bone loss and fractures through anti-apoptotic effects on bone cells.
Researchers have identified a protein in mice that regulates bone formation, finding that augmented osteoblast activity leads to elevated bone mass. The discovery could lead to new treatments for osteoporosis by targeting the Shn3 and WWP1 proteins.
Researchers found that slightly increasing NFATc1 activity leads to massive bone accumulation in mice, suggesting potential new targets for treating osteoporosis. The study's findings may enable the development of drugs that promote bone formation without causing undesirable side effects.
Chronic alcohol abuse can disrupt the balance of bone remodeling, leading to measurable bone loss over a few years. Alcohol-induced bone disease weakens bones and predisposes individuals to increased fracture risk and delayed fracture healing due to decreased osteoblast activity.
Researchers identify Twist proteins as transient inhibitors of osteoblast differentiation, negatively regulating Runx2. This finding provides insight into the complexity of osteoblast differentiation and its initiation by the relief of inhibition.
Researchers found that PPAR-gamma deficiency in mice enhances bone development by increasing osteoblast production, while adipocyte differentiation is impaired. This discovery may provide new avenues for osteoporosis therapies.
Researchers at the University of Rochester Medical Center have identified a key role for bone-forming osteoblasts in controlling the expansion of blood-forming stem cells. The discovery could lead to new treatments for bone marrow-transplant patients, who often face challenges due to limited stem cell availability.
The overproduction of noggin during aging may result in impaired bone building and function, leading to net bone loss. Researchers suggest that recombinant BMP2 may prove useful in reversing age-related bone loss.
IGFBP-5 promotes osteoblast function and bone formation in a manner distinct from IGF-I. The protein interacts with a receptor on osteoblasts to regulate cell growth and activity.
Researchers found that alcohol feeding impaired osteoblast function and led to increased bone turnover, contributing to bone fragility. In contrast, mice lacking the interleukin-6 (IL-6) gene had better maintained bone mass and reduced fractures.